ARCHIVES

PMC GROUP INTERNATIONAL announces acquisition of copperhead chemical company

Mount Laurel, NJ (February 22, 2021): PMC Group International, Inc., which is an independent arm of PMC Group Companies, announced the acquisition of Cobra Investments Management Inc. and its two subsidiaries, Copperhead Chemical Company Inc. (“Copperhead”) and Copperhead Investments Inc., from a group of previous owners of these entities, effective February 5, 2021. Copperhead is the manufacturing arm of the three acquired entities and is located on an 875 acres facility with 53 buildings in Tamaqua, Pennsylvania.

Copperhead has been the sole manufacturer of the FDA approved cardiac therapeutic drug nitroglycerin in the US for over 70 years and a custom manufacturer of drug dosage forms. It is also a major producer of energetic chemicals (explosives and propellants) for the defense industry as well as a novel class of preservatives and antimicrobials. Copperhead’s products are sold globally.

“The acquisition of Copperhead and its associated companies increases our penetration of the pharma market”, said Dr. Raj Chakrabarti, President of PMC Group International. According to Dr. Chakrabarti “this new acquisition will fit neatly and synergistically with our other Pharmaceutical services and manufacturing companies – especially PMC Isochem in France with three sites that include manufacturing of excipients and APIs as well as protein engineering, drug development and drug discovery services; and PMC YM-Pharma in Hyderabad, India, which provides process development and advanced pharmaceutical intermediate manufacturing services.” Dr. Raj Chakrabarti added that Copperhead will also have further manufacturing and marketing synergies with PMC Ouvrie, which is a leading supplier of defoamers, surfactants, and protective colloids for food and other industrial

applications. He further added that “with the acquisition of Copperhead, PMC Group International is now poised to provide an end-to-end CDMO offering spanning all phases of drug development and manufacturing across three continents.”

ABOUT PMC Group Companies:

PMC Group is a US based growth oriented, diversified, global chemicals and pharmaceuticals company dedicated to innovative solutions to every need in a broad range of end markets including, plastics, consumer products, electronics, coatings, packaging, mining, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation, and marketing platform with facilities in the Americas, Europe, and Asia. More information about PMC Group and its activities around the world can be found at www.pmc-group.com.

 

 

PMC Isochem to accelerate Polyamino acids business as part of ISODEL® Drug Delivery offer, a unique One Stop Shop for NCA and PAA

Based on its own internal resources and endowed with a fully integrated know-how as well as its leading position in the manufacture of critical Activated Amino Acids (NCA), PMC Isochem becomes the reliable supplier of PAA and the sustainable partner. PMC Isochem offers wide CDMO’s services from R&D to CMC and GMP custom manufacturing of complex Polyamino acids, including block copolymers, for the pharmaceutical industry innovators. PMC Isochem delivers to its clients much more than just the polymer from the monomers - the supply is secured from the readily available NCA raw material and benefits from 40 years of APIs GMP manufacturing experience for North America and European markets.

PMC Isochem ISODEL® offer at a glance:
• Vitamin E TPGS: a key functional excipient of several approved drug for which PMC Isochem is supplier for more than 10 years.
• Polyamino acids prepared from activated amino acids (N-CarboxyAnhydrides / NCA) are a unique entry point to biopolymer diversity, with great potential for applications in complex formulations and delivery technologies of small molecules and biologics.

About PMC Isochem PMC
Isochem provides product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates, active pharma ingredients (APIs) and functional excipients for major pharmaceutical companies worldwide to serve the medical needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. PMC Isochem facilities combine three sites in France-- Gennevilliers, Pithiviers, and Vert-Le-Petit -- within a 60 miles radius of Paris. The facilities are all GMP US-FDA audited plants for manufacturing pharmaceutical products. PMC Isochem with 230+ employees operates as a wholly owned subsidiary of PMC Group France.

About PMC
PMC Group is a growth oriented, diversified, global chemicals and plastics company dedicated to innovative solutions to everyday needs in a broad range of end markets including plastics, consumer products, electronics, paint, packaging, personal care, food, automotive and pharmaceuticals. The Company was built on a sustainable model of growth through innovation while promoting social good. PMC operates from a global manufacturing, innovation and marketing platform with facilities in the Americas, Europe and Asia. More information about PMC and its activities around the world can be found at www.pmc-group.com.

PMC Isochem invests 2 Millions € in R&D

PMC Isochem invests 2 Millions € in new R&D capability: new labs, Kilolab and new analytical technology equipment.

This R&D capability expansion will support CDMO and Polyamino acid based polymers for Drug delivery business growth.

Efficient transposition of the Sandmeyer reaction from batch to continuous process

Efficient transposition of the Sandmeyer reaction from batch to continuous process, Org. Process Res. Dev.

Joseph D'Attoma, Titi Camara, Pierre-Louis Brun, Yves Robin, Stephane Bostyn, Frédéric Buron, and Sylvain Routier Org. Process Res. Dev., Just Accepted Manuscript

DOI: 10.1021/acs.oprd.6b00318 • Publication Date (Web): 30 Nov 2016

A publication on continuous flow chemistry in the frame of Flowsyn collaborative project between the Institutes ICOA, ICARE (Orléans University and CNRS UMR7311, France) and ISOCHEM.